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Abstract
Background: Glomerular filtration rate (GFR) estimation is the gold standard for
assessment of renal function, although the clinical utility of this test is unclear.
Objectives: To describe the clinical utility of GFR estimation in dogs.
Animals: Medical records of 132 dogs that had serum iohexol clearance measured
between 2012 and 2017.
Methods: Iohexol clearance and clinical records were reviewed and submitting prac-
tices contacted to obtain outcome data. Dogs were classified into 4 groups based on
the reason for performing GFR estimation: A1 (screening for pre-azotemic chronic
kidney disease [CKD], n = 105), A2 (confirmation of azotemic CKD, n = 3), B (screen-
ing for pre-azotemic acute kidney injury, n = 19), and C (miscellaneous causes, n = 5).
Descriptive review of the clinical utility of GFR estimation is provided.
Results: For dogs in Group A1, renal disease was diagnosed in 9/9 dogs with a GFR
≥40% decreased below the mean GFR of their body weight category, in 5/6 dogs
with a ≥30% but <40% reduction in GFR and in 7/9 dogs with a ≥20% but <30%
reduction in GFR.
Conclusions and Clinical Importance: Glomerular filtration rate estimation is useful
for the diagnosis of CKD before the onset of azotemia.
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1 | INTRODUCTION
Accurately assessing renal function can be useful in dogs with suspected
kidney disease. Such situations include screening for renal dysfunction as
a cause of polyuria and polydipsia in dogs that are non-azotemic, have
only a borderline increase in serum creatinine concentration, have iso-
lated increases in novel markers such as symmetric dimethylarginine
(SDMA), or have persistently reduced urine concentrating ability.1 Other
indications include monitoring for progression of existing chronic kidney
disease (CKD), screening for renal dysfunction in breeds predisposed to
hereditary nephropathies,2 dosage adjustment of renally excreted drugs,
and monitoring the effects of chronic administration of potentially neph-
rotoxic drugs.3
Glomerular filtration rate (GFR) estimation is the gold standard for
assessment of renal function, as it is directly proportional to renal
mass.4 Glomerular filtration rate is estimated by assessing the clearance
of a marker of glomerular filtration.1 Urinary clearance of inulin is the
reference method for estimating GFR in humans and dogs. A more
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practical alternative is to measure the plasma/serum clearance of 1 or
more of various markers. Markers used to estimate GFR in animals
include inulin, exogenous creatinine, radionucleotides, and iohexol.5-8
Because of its ease of use, cost, and availability, plasma clearance of
iohexol has become 1 of the more widely used markers of GFR in vet-
erinary and human medicine.9-18
Techniques using limited sampling have been used in human and
veterinary medicine as a practical means to estimate GFR. When using
such techniques, a correction formula must be applied to achieve
more accurate approximations of GFR. The most widely used of these,
the Brøchner-Mortensen formula, has been extrapolated from human
medicine for use in veterinary studies19-21; however, a systematic
review of species differences has not been performed. More recently,
Bexfield et al. described a correction formula for estimation of GFR in
dogs using a 1-compartmental clearance technique taking dog weight
and age into account.21,22
Serum creatinine, a surrogate marker of GFR, has largely replaced
GFR estimation in clinical practice because of its availability, practical-
ity of measurement, and widespread use in monitoring and staging
kidney disease.23 However, serum creatinine is insensitive to early
decline in GFR because of the exponential relationship between
serum creatinine concentration and GFR. A further limitation is that
reference intervals for creatinine vary with animal size, yet laborato-
ries generally use 1 reference interval for all animals irrespective of
their size. Additionally, reference intervals vary between laboratories
depending on the method of measuring creatinine.24 Despite GFR
estimation being the gold standard for assessing renal function, it
remains infrequently used and data on the widespread clinical utility
of GFR estimation in clinical practice are lacking. The aim of this study
was to describe the clinical utility of GFR estimation determined by
serum iohexol clearance in dogs.
2 | MATERIALS AND METHODS
2.1 | Data acquisition and analysis
The medical records of dogs which had samples submitted for GFR
estimation by serum iohexol clearance to the Royal Veterinary College
(RVC) GFR/therapeutic drug monitoring service from March 9, 2012,
to November 4, 2017, were assessed. The project was reviewed and
approved by the RVC clinical research and ethical review board, which
allowed access to joint iohexol clearance test submission forms held
by deltaDOT Ltd and the RVC. Additionally, contact with the veteri-
narians for access to the clinical records of the dogs under investiga-
tion and for completion of a short questionnaire regarding outcomes
was approved. This contact was performed before the final implemen-
tation of the General Data Protection Regulation (EU) 2016/679.
2.2 | Iohexol clearance protocol
A standard protocol was recommended to veterinarians collecting
samples to be submitted for measurement of iohexol clearance. Dogs
were well hydrated at the time of the test, had free access to water
for 12 hours before testing, and had no clinical signs consistent with
dehydration or hypovolemia. Food was withheld for 12 hours before
testing. A single dose of iohexol (Omnipaque 300) was administered
at 300 mg iodine/kg IV through a catheter. The IV catheter was then
flushed with saline. Blood was collected into serum gel tubes precisely
at 2, 3, and 4 hours after iohexol administration. Exact times of blood
collection and iohexol administration were noted, and if there were dis-
crepancies with the protocol, the actual time between dose administra-
tion and sampling was used in the calculation. Blood was centrifuged
after clotting as per the centrifuge manufacturers' instructions for sepa-
ration of serum. The serum samples were shipped at room temperature
for next day delivery. Serum iohexol concentration for each serum sam-
ple was measured using deltaDOT Ltd's validated high-performance
capillary electrophoresis method.25 To correct for any variability in the
amount of sample injected onto the column, 3 μL of iopromide was
added to 57 μL of each sample (2-, 3-, and 4-hour post-iohexol serum
samples) as an internal standard and this was used to correct the
iohexol concentrations for variation in sample volume applied to the
system. Data were analyzed using deltaDOT Ltd's generalized separa-
tion transform.
Serum iohexol concentrations were used to calculate serum clear-
ance of iohexol. Glomerular filtration rate was estimated from the
serum clearance of iohexol by application of a compartmental model
and canine-specific correction formula,22 normalized to body weight in
kilograms. For data analysis, dogswere divided into 4weight quartiles; Cat-
egory 1:1.8-12.4 kg, Category 2:13.2-25.5 kg, Category 3:25.7-31.6 kg,
and Category 4:32.0-70.3 kg.22 In the event that a dog's body weight did
not fall within the range of 1 of these bodyweight categories, the dogwas
included in the bodyweight category towhich its bodyweightwas closest.
The estimated GFR of each dog was compared with the expected mean
GFRof their respective bodyweight categories: 2.89 mL/kg/min for Cate-
gory 1, 2.4 mL/kg/min for Category 2, 2.16 mL/kg/min for Category
3, and 2.25 mL/kg/min for Category 4.22
2.3 | Clinical case data collection
Standardized submission forms were provided to be completed by a
veterinarian with each GFR sample submission. Information requested
was: signalment; weight; the exact volume of Omnipaque 300 adminis-
tered; exact time of Omnipaque 300 administration and exact times
of each serum sample collection; reason for GFR testing and case
history (including current/previous medications and dose rates);
estimated/measured water consumption; previous serum creatinine
and SDMA concentrations; total/ionized blood calcium concentration;
urinalysis; urine culture; urine protein:creatinine ratio; ACTH stimula-
tion test results; low-dose dexamethasone suppression test results;
urine cortisol-to-creatinine ratio (UCCR); abdominal ultrasound find-
ings; blood pressure; serum total T4, free T4, and TSH concentrations;
and any other additional test results. When interpreting serum creati-
nine results, the reference intervals from the various laboratories to
which each individual sample was submitted for serum creatinine
measurement were used. When >1 serum creatinine concentration,
urine-specific gravity (USG), or UCCR result was provided for a dog,
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the median value was chosen for interpretation. Corrected GFR was
then interpreted with regard to the dogs' medical history by a special-
ist panel consisting of a diplomate of the European College of Veteri-
nary Pharmacology and Toxicology (ECVPT; J.E.), a joint diplomate of
the European College of Veterinary Anaesthesia and Analgesia and
the ECVPT (L.P.), and a diplomate of the American College of Veteri-
nary Internal Medicine (small animal internal medicine; R.E.J.).
The veterinarian(s) who submitted each sample set for iohexol
clearance to be measured was contacted via email and asked to com-
plete a short questionnaire regarding case outcomes. Data collected
included status (ie, alive/dead), date of euthanasia/death, reason for
euthanasia/death if known, diagnosis reached for the clinical sig-
ns/routine laboratory findings that prompted GFR estimation, evidence
for diagnosis of CKD (defined as persistently elevated creatinine or a
single identified episode of elevated creatinine above the laboratory
reference interval accompanied by inappropriately dilute urine [USG of
<1.030]), and if a diagnosis of CKD was obtained, the time between
GFR estimation and when evidence supporting a diagnosis of CKD was
obtained. For dogs that were alive, follow-up time was considered the
days between GFR estimation and date of contacting the submitting
veterinary surgeon. For dogs that were dead, follow-up time was con-
sidered the days between GFR estimation and death/euthanasia. If no
response to the questionnaire was received or the answers were insuf-
ficient to provide outcome information, the veterinarians were con-
tacted directly by telephone to request the full clinical history and
laboratory reports for the dogs in question from the time of iohexol
clearance sample submission to the time of follow-up.
2.4 | Case classification
Dogs were classified into 1 of 4 groups depending on the reason for
sample submission: Group A1: screening for non-azotemic CKD; Group
A2: confirmation of CKD with evidence of CKD already documented;
Group B: suspicion for non-azotemic acute kidney injury (AKI); and
Group C: miscellaneous reasons. These classifications were based on
review of data provided on the GFR submission forms. Group A1 cases
included those with non-azotemic polyuria and polydipsia, persistently
inappropriately dilute urine concentrating ability and abnormalities iden-
tified on abdominal ultrasound examination compatible with either
chronic nephropathy or renal dysplasia. Dogs with a borderline azote-
mia, defined as a creatinine value <0.3 mg/dL above the upper end of
the reference interval from the corresponding laboratory, and azotemic
dogs with a creatinine ≥0.3 mg/dL above the upper end of the refer-
ence interval from the corresponding laboratory but USG ≥1.030 were
included in this group. Group A2 cases included those where there had
been clinical suspicion for a diagnosis of CKD as per Group A1 but
where in addition there was at least 1 measurement of creatinine from
the submitting veterinarian that had been ≥0.3 mg/dL above their spe-
cific laboratory reference interval with concurrent USG <1.030, which
was considered consistent with CKD. One dog with a serum creatinine
concentration that was 0.54 mg/dL above the upper end of the refer-
ence interval with concurrent USG of 1.013 was included in Group A1
rather than in Group A2 as it was a Greyhound, a breed that has higher
serum creatinine concentrations than other dog breeds.26 For classifica-
tion into Groups A1 and A2, clinical changes were required to be
present for >1 month indicating chronicity. Group B included those
dogs in which there was suspicion for an AKI based on historical find-
ings and duration of clinical signs being <1 month, and included screen-
ing for cutaneous and renal glomerular vasculopathy (CRGV) in cases
that presented with unexplained skin lesions.27 Dogs not falling into
Groups A1, A2, or B were considered miscellaneous (Group C).
Glomerular filtration rate estimation results from individual dogs
in Groups A1, A2, and B were interpreted using categories of: GFR
Group 1: GFR increased or <20% decreased from the mean GFR of
the body weight category, kidney disease considered excluded or
unlikely as a cause of presenting clinical signs; GFR Group 2: ≥20%
but <30% decrease in GFR from the mean GFR of the body weight
category, kidney disease considered possible but unconfirmed as an
etiology for presenting clinical signs; GFR Group 3: ≥30% but <40%
decrease in GFR from the mean GFR of the body weight category,
kidney disease considered likely as an etiology for presenting clinical
signs; and GFR Group 4: ≥40% decrease in GFR from the mean GFR
of the body weight category, kidney disease considered almost certain
as an etiology for presenting signs. The criterion for GFR Group 1 was
based on the anticipated variability in iohexol clearance measurement
where the within individual variability for GFR estimation via iohexol
clearance has previously been reported as 19.9% for non-azotemic
cats.28 Criteria for Categories 3 and 4 were based on estimates of
GFR reduction that have been associated with the point at which
serum creatinine becomes elevated in previous studies.29
2.5 | Statistical analysis
Iohexol clearance submission forms and follow-up data from veterinarians
were analyzed. Descriptive analysis is provided with clinicopathological
data collected from submission forms and follow-up questionnaire/
telephone assessment presented as median (range) unless otherwise
stated. Dogs were grouped according to reason for GFR assessment
(Groups A1-C) and the following parameterswere evaluated: signalment,
weight, presenting complaint, laboratory diagnostics performed, GFR
(median and range), GFR analyzed by weight category, GFR % deviation
frommean, final diagnosis, and status at the time of follow-up.
3 | RESULTS
3.1 | Study population
A total of 132 dogs had samples submitted for GFR assessment
between March 9, 2012, and November 4, 2017.
Forty-six different breeds were represented in the study popula-
tion (not including cross-breeds). The most commonly represented
were Labrador Retrievers (n = 20), West Highland White Terriers
(n = 7), Border Collies (n = 7), Golden Retrievers (n = 6), Staffordshire
Bull Terriers (n = 6), and Boxers (n = 6). A full list of the represented
breeds is shown in Table 1.
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There were 70 females (7 intact, 50 neutered, and 13 of unspecified
neuter status) and 62 males (15 entire, 29 neutered, and 18 of
unspecified neuter status) in the study population. Ages ranged from
0.5 to 15.5 years with a median age of 6.2 years. Weight ranged from
2.45 to 59.3 kg with a median weight of 20.7 kg. Dogs were assigned
to 1 of 4 weight categories22 (Category 1:1.8-12.4 kg, n = 30; Category
2:13.2-25.5 kg, n = 55; Category 3:25.7-31.6 kg, n = 21; and Category
4:32.0-70.3 kg, n = 26). One dog's body weight (25.55 kg) did not fall
within the previously described ranges of these body weight categories;
this dog was ultimately included in body weight Category 1 given that
its body weight was nearer to the upper limit of category 1 (25.5 kg)
than the lower limit of Category 2 (25.7 kg).
Samples were submitted from 3 countries: the United Kingdom
(n = 127), Norway (n = 3), and Denmark (n = 2). Seventy-seven
samples were submitted from diplomates of the European or
American College of Veterinary Internal Medicine, Royal College of
Veterinary Surgeons (RCVS)-recognized specialists in small animal
internal medicine or by residents working under the supervision of
the aforementioned diplomates. Fifty-four samples were submitted
from general practitioner veterinarians. It was unknown whether
1 sample was submitted from a specialist or general practitioner
because of lack of information on the submission form. Submission
form information was available for all 132 dogs. Follow-up data were
available for 81% (107/132) of dogs: questionnaire evaluation in
47/132 cases and telephone follow-up was required in 60/132 cases.
The time between GFR estimation and when the submitting veterinar-
ians was contacted (n = 132) ranged from 2 to 1350 days with a
median of 402 days. Survival time for those dogs that had died or
been euthanized was a median of 325 days (range, 2-849). In all dogs
for which follow-up data were available, a final diagnosis was reached
in 75.7% (81/107) of cases.
3.2 | Glomerular filtration rate estimation
Median GFR was 2.15 mL/kg/min across all body weight categories
with a range of 1.03-4.04 mL/kg/min. Percentage deviation from the
mean of the body weight category ranged from −78.6 to +68.0% with
a median deviation of −12% from the mean. When GFR estimation
results from all dogs were analyzed together by body weight catego-
ries, the results were:
• Body weight Category 1 (1.8-12.4 kg): median GFR 2.66 mL/kg/min
(range, 1.3-4.04 mL/kg/min); median % deviation in GFR from
bodyweight category mean −9.45% (range, −55 to +42.9%).
• Body weight Category 2 (13.2-25.5 kg): median GFR 2.22 mL/kg/min
(range, 1.2-4.03 mL/kg/min); median % deviation in GFR from
bodyweight category mean −7.05% (range, −50 to +68%).
• Body weight Category 3 (25.7-31.6 kg): median GFR 1.83 mL/kg/min
(range 1.09-3.23 mL/kg/min); median % deviation in GFR from
bodyweight category mean −15.55% (range, −49.5 to +49.5%).
• Body weight Category 4 (32.0-70.3 kg): median GFR 1.83 mL/kg/min
(range, 1.03-3.1 mL/kg/min); median % deviation in GFR from
bodyweight category mean −14.49% (range, −54.5 to +37.6%).
Glomerular filtration rate estimation results per body weight cate-
gory are represented graphically in Figure 1.
3.3 | Clinical case evaluation
Dogs were categorized based on presenting reason for GFR assess-
ment before further analysis; Group A1, n = 105; Group A2, n = 3;
Group B, n = 19; and Group C, n = 5. Clinical signs, signalment, and
laboratory findings for dogs based on reason for presentation groups
are presented in Tables 2 and 3. Of the dogs in Group A1, 4 had
suspected renal dysplasia based on imaging findings and on their age
being <1 year. Of dogs in Group B, 17 were being screened for pre-
azotemic AKI because of suspected CRGV, 1 had suspected AKI
because of recent raisin ingestion, and 1 had suspected AKI because
of recent jerky treat ingestion. Of the 5 dogs in Group C (miscella-
neous causes), 3 were undergoing chemotherapy and had GFR esti-
mation performed to assess the need for carboplatin dose adjustment
and in the case of the remaining 2 dogs insufficient information was
available on the submission forms to establish the reason for GFR
estimation and follow-up information could not be obtained. Data
TABLE 1 Dog breeds represented in the study population
Number of dogs Breed(s)
20 Labrador Retriever
7 West Highland White Terrier, Border Collie
6 Golden Retriever, Staffordshire Bull Terrier, Boxer
4 Greyhound, Lurcher
3 Springer Spaniel, Cocker Spaniel, Hungarian Vizsla, Beagle
2 German Shorthaired Pointer, German Shepard, Jack Russell Terrier, Doberman Pinscher, Yorkshire Terrier, Border Terrier, Pug
1 Japanese Akita, Australian Shepard, Australian Cattle Dog, Bearded Collie, Havanese, Dalmatian, Dachshund, English Bull
Terrier, English Setter, Flat-coated Retriever, French Bulldog, Giant Schnauzer, Great Dane, Irish Setter, Kerry Blue Terrier,
Alaskan Malamute, Papillon, Pomeranian, Poodle, Rottweiler, Saluki, Shar Pei, Shetland Sheepdog, Shih Tzu, Swiss
Mountain Dog, Weimaraner, Welsh Springer Spaniel
19 Cross-breeds
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relating to GFR estimation and percentage change in GFR for all dogs,
and divided according to body weight category per reason for presen-
tation group, are presented in Table 3. A full list of the tests per-
formed before GFR estimation in dogs in Groups A1, A2, B, and C is
provided in Supplemental Table 1.
A total of 47 (35.6%) dogs across Groups A1-C were receiving
medications at the time of GFR estimation. Of these, 18 were receiv-
ing medications that could influence GFR (angiotensin-converting
enzyme-inhibitors n = 9, glucosamine n = 3, levothyroxine n = 3,
angiotensin-receptor antagonist n = 1, prednisolone n = 1, and topical
prednisolone n = 1). Details on drugs being administered at the time
of GFR estimation in each group are presented in Table S2.
3.4 | Evaluation of outcome data: Group A1
3.4.1 | Diagnosis
In Group A1, follow-up data were available for 79 cases and on review
of this information a final diagnosis was reached in 77% (61/79).
Overall, the most common diagnoses reached in Group A1 were psy-
chogenic polydipsia (n = 15), progressive CKD (n = 15), protein-losing
nephropathy (PLN, n = 4), and central diabetes insipidus (n = 4). Diag-
noses were further analyzed based on dog GFR categorization as
described in Figure 2. In 9/9 (100%) dogs for which a follow-up diag-
nosis was available and that had a GFR decrease of ≥40% below the
mean GFR for their bodyweight category (GFR Group 4), a renal etiol-
ogy was ultimately diagnosed for their clinical signs or laboratory find-
ings that prompted GFR estimation. Five of 6 dogs (83.3%) with an
available final diagnosis in GFR Group 3 (≥30% but <40% reduction in
GFR) and 7/9 (77.8%) dogs with an available final diagnosis in GFR
Group 2 (≥20% but <30% reduction in GFR) were ultimately diagnosed
with a renal etiology of their presenting clinical signs. Five of 37 dogs
(13.5%) with an available diagnosis in GFR Group 1 (GFR increased or
<20% reduction in GFR) were ultimately diagnosed with a renal etiol-
ogy of their presenting clinical signs. Of the remaining 32 dogs in GFR
Group 1 that were diagnosed with a nonrenal etiology of their pre-
senting clinical signs, none developed progressive CKD during the
follow-up period.
3.4.2 | Development of azotemia
Of the 103 dogs in Group A1 for which serum creatinine was available
at the time of GFR estimation, 23 (22%) dogs had azotemia docu-
mented before GFR estimation, whereas 80 (78%) dogs were not azo-
temic. In 18 of the 23 azotemic cases, the azotemia was considered
borderline, that is, ≤0.3 mg/dL above the upper end of the laboratory
TABLE 2 Clinical presenting complaints and reasons for dogs
presenting for glomerular filtration rate (GFR) estimation
Clinical sign/laboratory
finding Group A1 Group A2 Group B Group C
Polyuria-polydipsia 71 1 3 -
Azotemia 26 3 1
Urinary incontinence 18 1 2 -
Proteinuria 13 - - -
Isosthenuria 12 - - -
Increased SDMA 6 - 1 -
Abnormal kidneys
on imaging
5 - - -
Lethargy 4 - 1 -
Hematuria 3 1 1 -
Nocturia 3 - - -
Inappropriate urination 3 - - -
Weight loss 3 - - -
Hypertension 3 - - -
Therapeutic
drug monitoring
- - - 3
Hyposthenuria 1 1 - -
Inappropriately
concentrated urine
2 - - -
Polydipsia 2 - - -
Polyuria 2 - - -
Increased urea 2 - - -
Vomiting 2 - - -
Inappetence 1 - - -
Renal mass on imaging 1 - - -
Recent jerky
treat ingestion
- - 1 -
Research purposes
(details unspecified)
- - - 1
Skin lesions - - 17 -
Recent raisin ingestion - - 1 -
Abbreviation: SDMA, symmetric dimethylarginine.
F IGURE 1 Glomerular filtration rate (GFR) estimation results
(mL/kg/min) represented graphically, separated by patient body
weight Categories 1-4. Each dot represents the GFR result from a
patient. The area on each chart with a green background represents a
GFR decrease of <20% from the mean GFR of the body weight
category, the yellow background represents a GFR decrease of ≥20%
but <30% from mean GFR, the orange background represents a ≥30%
but <40% decrease in GFR from mean GFR, and the red background
represents a ≥40% decrease in GFR from the mean GFR
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reference interval for creatinine. In the remaining 5 cases, the creati-
nine was >0.3 mg/dL above the upper end of the laboratory reference
interval but 3 dogs were included in Group A1 because of their USG,
which was well concentrated, suggesting a potential prerenal compo-
nent contributing to azotemia (USG 1.030, 1.034, 1.042) and in 2 cases
because of being a Greyhound.26 Six dogs in Group A1 that were
not azotemic at the time of GFR estimation and were ultimately
diagnosed with progressive CKD developed azotemia during the
follow-up period, with median time between GFR estimation and
documentation of azotemia of 335 days (range, 76-827 days).
TABLE 3 Signalment and clinicopathological variables for dogs presenting for glomerular filtration rate (GFR) estimation
Group A1 (n = 105) Group A2 (n = 3) Group B (n = 19) Group C (n = 5)
Median (range) N Median (range) N Median (range) N Median (range) N
Age (y) 6.25 (0.5-14) 7.8 (5.4-10) 6 (1-11.2) 4.1 (3-15.6)
Body weight (kg) 20.88 (2.45-59.3) 30.5 (19.1-41.7) 19.6 (6.7-41.5) 18 (4.5-32.6)
Weight category
1 9.3 (2.5-12.4) 65 - - 9.1 (3.42-12.4) 4 6.3 (4.5-8) 2
2 20.38 (13.2-25.55) 12 19.1 1 18.1 (13.5-21.3) 10 21.5 (18-24.9) 2
3 28.8 (25.8-30.3) 12 28.6 1 29.3 (27.9-31.5) 3 - -
4 38 (32-59.3) 16 41.7 1 38.6 (35.6-41.5) 2 32.6 1
Sex
FN 43 - 7 -
FE 5 - 2 -
F (unknown neuter status) 11 - 2 -
MN 22 3 3 1
ME 12 - 2 1
M (unknown neuter status) 12 - 3 3
Creatinine (mg/dL) 97 (26-233) 103 157 (156-183) 3 96 (70-165) 19 136 (128-149) 4
Symmetric
dimethylarginine (μg/dL)
15 (8-25) 6 - - 8 1 - -
USG 1.015 (1.005-1.042) 98 1.013 (1.008-1.025) 3 1.042 (1.015-1.055) 14 1.030 (1.020-1.040) 4
UPC 0.16 (0-23.4) 87 0.15 (0.05-1.45) 3 0.12 (0-0.2) 5 0.07 (0.03-0.36) 3
Urine culture
Total in which performed 87 3 3 1
Positive 7 0 1 -
Negative 79 3 2 1
Result unknown 1 - - -
GFR (mL/kg/min) 2.12 (1.09-4.04) 1.37 (1.03-1.4) 2.58 (1.72-3.96) 1.75 (1.3-3.92)
GFR (mL/kg/min) by
weight category
1 2.58 (1.5-4.04) - 2.74 (2.52-3.56) 2.62 (1.3-3.92)
2 2.18 (1.2-4.03) 1.38 2.77 (2.05-3.96) 1.94
3 1.83 (1.09-2.67) 1.4 2.5 (1.72-3.23) 1.75
4 1.87 (1.23-3.1) 1.03 2.11 (2.01-2.21) 1.48
Percentage change in GFR
compared to body weight
GFR category
−12.6 (−50 to +68) −42.4 (−54.4 to −35.2) 0 (−20.4 to +65) −27.3 (−55 to +35.6)
Percentage change in GFR compared to body weight GFR category by weight category
1 −10.8 (−48 to +40.8) - −5.4 (−12.8 to +23.7) −9.7 (−55 to +35.6)
2 −7.8 (−46.7 to +68) −42.4 15.2 (−14.6 to +65) −19
3 −15.6 (−49.5 to +23.5) −35.2 15.6 (−20.4 to +49.5) 35.6
4 −16.9 (−43.5 to +37.6) −54.4 −6.2 (−10.7 to −1.8) −27.3
Abbreviations: UPC, urine protein-to-creatinine ratio; USG, urine specific gravity.
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3.4.3 | Status
Data pertaining to status was available for 83 (79%) dogs in Group A1.
Sixty-seven dogs were alive at the time of follow-up, while 16 dogs had
died. For those dogs that had died, median time between GFR estima-
tion and death/euthanasia was 326 days (range, 2-914 days). A reason
for death/euthanasia was available for 16/18 dogs. Causes of
death/euthanasia included neoplasia (n = 3), spinal cord disease (n = 2),
age-related poor quality of life (n = 2), acute gastroenteritis (n = 2), uro-
abdomen (n = 1), pancreatitis (n = 1), meningoencephalitis of unknown
etiology (n = 1), cluster seizures (n = 1), and progression of renal dyspla-
sia (n = 1).
F IGURE 2 Distribution of dogs in Group A1 (glomerular filtration rate [GFR] estimation performed to screen for pre-azotemic chronic kidney
disease) and documented outcome
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3.5 | Evaluation of outcome data: Group A2
In Group A2, follow-up data were available for 2 of 3 cases. All 3 dogs
in Group A2 were assessed to have been diagnosed with CKD before
GFR estimation on the basis of overt azotemia (creatinine 2.0, 1.76,
and 1.78 mg/dL), and follow-up data confirmed the diagnosis of CKD
in both dogs for which these data were available. Glomerular filtration
rate categorization for Group A2 showed that in 1 dog, GFR was
reduced by ≥30% but <40%, and in 2 dogs ≥40% commensurate with
their documented azotemia. Both dogs for which follow-up data were
available were alive at the time of follow-up.
3.6 | Evaluation of outcome data: Group B
3.6.1 | Diagnosis
In Group B, follow-up data were available for 15/19 cases and on
review of this information a final diagnosis was reached in 100%
(15/15). The most common diagnosis was a nonspecified dermatopathy
(n = 13), whereas the remaining 2 dogs were considered clinically nor-
mal. Diagnoses were further analyzed based on GFR categorization as
described in Figure 3. No dogs (0/15) in GFR Group 1 were ultimately
diagnosed with a renal etiology of their clinical signs. Similarly, no dogs
(0/1) in GFR Group 2 were ultimately diagnosed with a renal etiology
of their clinical signs.
3.6.2 | Development of azotemia
Three out of 19 dogs in Group B had azotemia documented before
GFR estimation, whereas the remaining 16 dogs in Group B were not
azotemic. In all 3 azotemic cases, the azotemia was considered border-
line, that is, <0.3 mg/dL above the upper end of the laboratory refer-
ence interval for creatinine. No dogs in Group B developed azotemia
during the follow-up period.
3.6.3 | Status
All 15 dogs for which follow-up data were available were alive at the
time of follow-up and none had gone on to develop progressive CKD.
3.7 | Evaluation of outcome data: Group C
Glomerular filtration rate categorization for Group C showed that in
1 dog GFR was reduced by <20%, in 1 dog GFR was reduced by
≥30% but <40%, and in 1 dog ≥40%. Follow-up data pertaining to
whether or not carboplatin dose was adjusted based on GFR estima-
tion was only available for 1 of 3 dogs. This dog had a 19% reduction
in GFR from the mean of its body weight category and did not have
carboplatin dose adjusted. Follow-up data pertaining to status were
available for all 3 dogs. Two dogs were dead and 1 was alive at the
time of follow-up. Of the 2 dead dogs, 1 was euthanized because of
metastatic colonic adenocarcinoma 288 days after GFR estimation.
The date and cause of death of the other dog was unknown.
4 | DISCUSSION
This study demonstrates the clinical utility of GFR estimation in dogs.
In Group A1 for which GFR estimation was performed for suspicion
of pre-azotemic CKD, using our preliminary categorization criteria,
F IGURE 3 Distribution of dogs in Group B (glomerular filtration rate [GFR] estimation performed to screen for pre-azotemic acute kidney
injury) and documented outcome
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100% of dogs in GFR Group 4, 83.3% of dogs in GFR Group 3, and
77.8% of dogs in GFR Group 2 (for which final diagnoses were avail-
able) were ultimately diagnosed with a renal etiology of their clinical
signs or laboratory findings that prompted GFR estimation. These
results suggest that the decline in GFR is detectable before the onset
of azotemia in this subgroup of dogs, with GFR estimation therefore
contributing to the diagnostic investigation. Relatively few (n = 6)
dogs had SDMA measurements performed by their local veterinarian;
therefore, based on the data provided, it was impossible to determine
whether SDMA would have indicated reduced renal function in these
dogs where creatinine concentration had not done so.
One dog in each of GFR Groups 2 and 3 (GFR reduction of ≥20%
but <30% and ≥30% but <40%, respectively) was considered clinically
normal by the submitting veterinarians at the time of follow-up.
Unfortunately, this assessment was based on spontaneous resolution
of the dogs' clinical signs (polyuria-polydipsia in both cases) rather
than on longitudinal monitoring of their kidney function. Therefore, the
authors cannot exclude the possibility that these dogs had undetected
kidney disease at the time of follow-up, and that progression of kidney
disease could have been documented either through serial assessment
of serum creatinine concentration or repeat GFR estimation. The ulti-
mate classification of these dogs as normal can therefore be questioned.
Other possible explanations were that the GFR estimation results in
these 2 dogs were erroneous, or that the dogs did indeed have CKD but
had a transient GFR reduction that later returned to normal; after the
loss of nephrons, the kidney adapts via hyperfiltration of the remaining
nephrons.30,31 This compensatory response could have led to a return of
GFR back forwards normal and a subsequent resolution in clinical signs.
A range of diagnoses were obtained in dogs in Group A1 that
demonstrated an increase or up to 20% reduction in their GFR value
(GFR Group 1). However, in 5 of the 37 (14%) dogs in this GFR cate-
gory for which a final diagnosis was available, a renal etiology of the
dog's clinical signs was ultimately obtained (PLN, n = 2; idiopathic
renal hematuria, n = 1; progressive CKD, n = 1; and pyelonephri-
tis, n = 1).
The 3 dogs classified into Group A2 were assessed to already have
a diagnosis of CKD based on the data provided by submitting veteri-
narians. In these dogs, the authors believe that performing GFR esti-
mation was not indicated, given these dogs already had definitive
evidence of CKD based on their historical creatinine, USG +/− renal
ultrasonographic findings. If dogs already had a diagnosis of azotemic
CKD, GFR estimation provided no additional diagnostic benefit unless
the authors were unaware, for example, of the requirement for drug
dosage adjustment. However, it is possible that GFR estimation could
help in longitudinal monitoring of dogs with azotemic CKD in which
creatinine might not change as GFR drops because of muscle atrophy;
having a baseline GFR at the time of diagnosis of CKD with which to
compare subsequent GFR estimations could be helpful in this group
of dogs.
Glomerular filtration rate estimation was also useful in ruling out
AKI in dogs classified into Group B. No dogs (0/15) in GFR Group 1 or
GFR Group 2 (0/1) were ultimately diagnosed with a renal etiology of
their clinical signs. A GFR result that was increased or <20% decreased
below the mean GFR of the dog's bodyweight category reliably
excluded pre-azotemic AKI. Obtaining a GFR result ≥20% but <30%
decreased below mean GFR could also be reliable for excluding
pre-azotemic AKI; however, the fact that a final diagnosis was only
available for 1 dog in this GFR category means it is impossible to
accurately determine this in our study. The unusual demographic of
idiopathic dermatopathy given as a final diagnosis in many of these
cases reflects the recent emergence of cutaneous renal glomerular
vasculopathy in the United Kingdom.27
This study has multiple limitations. First, the study was retrospec-
tive in nature and the study population was relatively small. Submis-
sions came from many different practices, including referral centers
and general practices. There is therefore inherent variation in the
extent and quality of the diagnostic investigation that was performed
in dogs before and after GFR estimation. This led to difficulties in
terms of reaching final diagnoses for some dogs. The clinical histories
of dogs for which a confirmed final diagnosis was reported by submit-
ting veterinarians were reviewed by the authors; if there was a high
level of confidence that the diagnosis reported accounted for the
dogs' presenting reason for GFR estimation, the dogs were assessed
to have a confirmed final diagnosis. If the diagnosis was assessed to
be presumptive, or incorrect, then the dogs were recorded as not hav-
ing a confirmed final diagnosis. Given that we did not directly examine
dogs or perform the diagnostic workup in the study population, it is
possible that our interpretation of the final diagnoses could be inaccu-
rate for some dogs. This study relied on submitting veterinarians fol-
lowing a standard protocol to measure iohexol clearance. To the best
of our knowledge, the recommended protocol was followed by sub-
mitting veterinarians, but we acknowledge the possibility that in some
cases deviation from the protocol could have occurred with subse-
quent effects on the results. The authors also acknowledge that inter-
individual and intraindividual variability in GFR exists, which could
lead to some dogs with normal kidney function ultimately being clas-
sified into GFR Groups 2 or, less likely GFR Group 3, where kidney
disease is considered possible or likely respectively. The different
veterinary practices submitting for GFR estimation used a variety of
laboratories for measuring serum creatinine, such that different ref-
erence intervals were used for each individual dog in this study and
to determine whether the dogs were initially azotemic or not at the
time of GFR submission. A further limitation is that clinical history
and important clinicopathologic data such as serum creatinine and
USG were missing for some dogs at the time of GFR estimation,
making interpretation of their GFR result more challenging. Finally,
follow-up data were not available for all dogs that had GFR estima-
tion performed, limiting the amount of longitudinal information avail-
able for assessment of the clinical utility of GFR estimation and
resulting in the ultimate number of dogs, where progression of renal
disease could be assessed, being relatively small.
The authors acknowledge that using breed-specific reference ranges
for creatinine or serial monitoring of creatinine concentrations could
increase the sensitivity of creatinine for detection of CKD or AKI. Given
that creatinine values for this study came from many different laborato-
ries using different reference intervals, comparing the sensitivity of GFR
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estimation for the detection of pre-azotemic CKD or AKI to the use of
breed-specific creatinine reference intervals or serial creatinine measure-
ments was not possible. Such a comparison could be a focus for future
study. Future studies are also required to compare the clinical utility of
GFR estimation for detecting pre-azotemic CKD and AKI to other bio-
markers, for example, SDMA which was infrequently available in this
population of dogs. Longer term studies would be required to better
evaluate the predictive capacity of GFR estimation for the future devel-
opment of azotemic CKD.
In conclusion, in our population of dogs, GFR estimation via
iohexol clearance was useful for the diagnosis of CKD before the
onset of azotemia and for ruling out pre-azotemic AKI. In dogs that
already had a diagnosis of azotemic CKD, GFR estimation provided
no additional diagnostic benefit. Based on data from previous
publications,32 GFR estimation is also useful to screen for the need
for carboplatin dose adjustment in dogs undergoing chemotherapy,
although it was not possible to determine the clinical utility of GFR
estimation for this purpose in our study because of lack of follow-up
data from this subset of dogs. The clinical utility of GFR estimation
must be balanced against the theoretical risk for iohexol administra-
tion to contribute to an AKI.33
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